Jeff Yass’s Kura Oncology KURA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.53M | Buy |
321,500
+254,500
| +380% | +$2.4M | ﹤0.01% | 5297 |
|
|
2026
Q1 | $545K | Sell |
67,000
-60,600
| -47% | -$521K | ﹤0.01% | 9438 |
|
|
2025
Q4 | $1.33M | Buy |
127,600
+114,500
| +874% | +$1.2M | ﹤0.01% | 6539 |
|
|
2025
Q3 | $116K | Sell |
13,100
-9,600
| -42% | -$68.4K | ﹤0.01% | 11471 |
|
|
2025
Q2 | $131K | Sell |
22,700
-18,200
| -44% | -$112K | ﹤0.01% | 11605 |
|
|
2025
Q1 | $270K | Sell |
40,900
-21,600
| -35% | -$168K | ﹤0.01% | 10289 |
|
|
2024
Q4 | $544K | Buy |
62,500
+40,100
| +179% | +$577K | ﹤0.01% | 8460 |
|
|
2024
Q3 | $438K | Sell |
22,400
-57,800
| -72% | -$1.17M | ﹤0.01% | 8790 |
|
|
2024
Q2 | $1.65M | Sell |
80,200
-21,200
| -21% | -$436K | ﹤0.01% | 5472 |
|
|
2024
Q1 | $2.16M | Buy |
+101,400
| New | +$1.97M | ﹤0.01% | 5146 |
|
|
2023
Q3 | – | Sell |
-22,400
| Closed | -$237K | – | 12516 |
|
|
2023
Q2 | $237K | Buy |
22,400
+10,600
| +90% | +$125K | ﹤0.01% | 9926 |
|
|
2023
Q1 | $144K | Sell |
11,800
-11,500
| -49% | -$144K | ﹤0.01% | 10948 |
|
|
2022
Q4 | $289K | Sell |
23,300
-106,000
| -82% | -$1.54M | ﹤0.01% | 9181 |
|
|
2022
Q3 | $1.77M | Buy |
129,300
+71,800
| +125% | +$1.11M | ﹤0.01% | 5181 |
|
|
2022
Q2 | $1.05M | Sell |
57,500
-7,300
| -11% | -$105K | ﹤0.01% | 6398 |
|
|
2022
Q1 | $1.04M | Sell |
64,800
-36,700
| -36% | -$530K | ﹤0.01% | 7006 |
|
|
2021
Q4 | $1.42M | Buy |
+101,500
| New | +$1.64M | ﹤0.01% | 6337 |
|
|
2021
Q3 | – | Sell |
-131,500
| Closed | -$2.74M | – | 13184 |
|
|
2021
Q2 | $2.74M | Sell |
131,500
-138,000
| -51% | -$3.43M | ﹤0.01% | 5222 |
|
|
2021
Q1 | $7.62M | Buy |
269,500
+173,300
| +180% | +$5.48M | ﹤0.01% | 3211 |
|
|
2020
Q4 | $3.14M | Buy |
96,200
+51,200
| +114% | +$1.8M | ﹤0.01% | 4228 |
|
|
2020
Q3 | $1.38M | Buy |
45,000
+24,900
| +124% | +$550K | ﹤0.01% | 5354 |
|
|
2020
Q2 | $328K | Buy |
+20,100
| New | +$290K | ﹤0.01% | 8190 |
|
|
2020
Q1 | – | Sell |
-12,900
| Closed | -$177K | – | 10591 |
|
|
2019
Q4 | $177K | Buy |
+12,900
| New | +$191K | ﹤0.01% | 8848 |
|
|
2019
Q2 | – | Sell |
-32,900
| Closed | -$546K | – | 10562 |
|
|
2019
Q1 | $546K | Buy |
+32,900
| New | +$507K | ﹤0.01% | 6097 |
|
|
2018
Q4 | – | Sell |
-13,400
| Closed | -$235K | – | 9491 |
|
|
2018
Q3 | $235K | Buy |
13,400
+3,200
| +31% | +$61.3K | ﹤0.01% | 7939 |
|
|
2018
Q2 | $186K | Buy |
+10,200
| New | +$173K | ﹤0.01% | 8677 |
|
Other funds holding KURA
SCM
BI
AC
ACM
Jeff Yass's KURA Position: Q2 2026 in Review
Jeff Yass reduced its Kura Oncology (KURA) stake by 84% in Q2 2026, selling an estimated $783K and leaving 15,576 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #12095.
Jeff Yass first reported a position in KURA in Q1 2017 and has held it in 28 quarters since. The position peaked at $12.7M in Q1 2024. 219 funds tracked by Wall St. Rank hold KURA as of Q2 2026.
- Jeff Yass held 15,576 shares of Kura Oncology worth $171K as of Q2 2026.
- Jeff Yass sold 83,016 Kura Oncology shares in Q2 2026, an estimated $783K.
- Kura Oncology made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12095 holding.
- Jeff Yass first reported a position in Kura Oncology in Q1 2017 and has held it in 28 quarters since.
- Jeff Yass's Kura Oncology position peaked at $12.7M in Q1 2024.
- 219 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.